| 1 |
25437886 | Endothelial progenitor cells induce transplant arteriosclerosis via VEGFR-1/2 activity. | 2015 Jan |
1 |
| 2 |
22611027 | Vandetanib, an inhibitor of VEGF receptor-2 and EGF receptor, suppresses tumor development and improves prognosis of liver cancer in mice. | 2012 Jul 15 |
1 |
| 3 |
20647338 | Vascular endothelial growth factor receptor 2-targeted chemoprevention of murine lung tumors. | 2010 Sep |
1 |
| 4 |
19528456 | Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474). | 2009 Jun |
6 |
| 5 |
15867254 | Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. | 2005 May 1 |
1 |
| 6 |
16140331 | The effects of ZD6474, an inhibitor of VEGF signaling, on cutaneous wound healing in mice. | 2005 Dec |
1 |
| 7 |
14760102 | Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. | 2004 Jan 15 |
2 |
| 8 |
15623658 | Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach. | 2004 Dec 15 |
3 |
| 9 |
15886878 | The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma. | 2004 |
1 |
| 10 |
14612898 | Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours. | 2003 Nov 17 |
2 |